Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.24.35 (matrix metalloproteinase 9)
 2,207 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The study of the serum levels of matrix metalloproteinase 9 (MMP9) and tissue inhibitor of matrix metalloproteinases type 1 (TIMP1) was conducted involving 108 patients aged over 65, with calcinosis and/or calcific aortic valve (AV) stenosis. The purpose of the study was to identify the molecular and genetic markers responsible for the development of senile aortic stenosis. Besides, there was also typing of polymorphic loci of MMP9 gene A8202G (rs1169732) and TIMP1 gene C536T(rs11551797) performed. The comparison group included 46 patients whose examination revealed no evidence of AV calcinosis present in them. Association of senile aortic stenosis with a significant increase in the serum TIMP1 levels (257,5 (151,5-325,9) pg/ml vs 129,7 (86,2-229) pg/ml, p < 0.05) has been detected, while the TIMP1 concentration going beyond 258,1 pg/ml in the elderly people over 65 years can be considered as a high-precision marker of the pathology under discussion. The MMP9 (A8208G) as well as TIMP1 (C5367) genetic polymorphisms are not associated with calcific aortic stenosis.
 ...
PMID:[MATRIX METALLOPROTEINASE 9 AND TISSUE INHIBITOR OF MATRIX METALLOPROTEINASES TYPE 1 SERUM CONCENTRATIONS AND GENETIC POLYMORPHISM IN SENILE AORTIC STENOSIS]. 2685 83